Clinical trial
Dose Ranging Study With LT, Monotherapy, PPAR
NCT00240383 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00240383 |
|---|---|
| Title | Dose Ranging Study With LT, Monotherapy, PPAR |
| Official title | A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus II |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 1,260 |
| Start date | May 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | Sep 14, 2010 |
| Countries | Argentina, Australia, Brazil, Canada, Czechia, France, Italy, Mexico, Netherlands, Poland, Puerto Rico, South Africa and 4 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: